Dr. Lucie M. Turcotte
Claim this profileUniversity of Minnesota/Masonic Cancer Center
Studies Langerhans Cell Histiocytosis
Studies Histiocytosis
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Lucie M. Turcotte is currently running
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
Vinblastine/Prednisone vs. Cytarabine
for Histiocytosis
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.
Recruiting4 awards Phase 33 criteria
More about Lucie M. Turcotte
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Lucie M. Turcotte has experience with
- Cytarabine
- Vinblastine
- Prednisone
- Multi-component Mobile Health And Social Media Physical Activity Intervention
- Wearing A Physical Activity Tracker Alone
- Web-Based Physical Activity Intervention
Breakdown of trials Lucie M. Turcotte has run
Langerhans Cell Histiocytosis
Histiocytosis
Cancer
Tumors
Blood Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lucie M. Turcotte specialize in?
Lucie M. Turcotte focuses on Langerhans Cell Histiocytosis and Histiocytosis. In particular, much of their work with Langerhans Cell Histiocytosis has involved treating patients, or patients who are undergoing treatment.
Is Lucie M. Turcotte currently recruiting for clinical trials?
Yes, Lucie M. Turcotte is currently recruiting for 2 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Lucie M. Turcotte has studied deeply?
Yes, Lucie M. Turcotte has studied treatments such as Cytarabine, Vinblastine, Prednisone.
What is the best way to schedule an appointment with Lucie M. Turcotte?
Apply for one of the trials that Lucie M. Turcotte is conducting.
What is the office address of Lucie M. Turcotte?
The office of Lucie M. Turcotte is located at: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota 55455 United States. This is the address for their practice at the University of Minnesota/Masonic Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.